Peyronies Society Forums

Please login or register.

Login with username, password and session length
Advanced search  

News:

ALL Members PLEASE Add a Signature line with age, history etc
PROFILE -> FORUM PROFILE -> SIGNATURE
More instructions here -> Signature Line - History - Peyronies Society Forums

Pages: [1]   Go Down

Author Topic: Covid 19 may be helpful  (Read 656 times)

0 Members and 1 Guest are viewing this topic.

Jack1909

  • Major Contributor
  • ****
  • Country: it
  • Offline Offline
  • Gender: Male
  • Posts: 510
Covid 19 may be helpful
« on: June 19, 2020, 09:24:11 AM »

Looking at the bright side, from our specific point of view, my brother is a covid doctor in Berlin and he told me many ex covid patients already dismissed are getting back at his office complaining breathing issues, some in a middle of respiratory crisis. They may have fibrosis in the lungs and the research for antifibrotic drugs speed up.
Logged
Please go to PROFILE then FORUM PROFILE to replace this signature line text with your profile info such as
age, date of onset, symptoms, treatments tried,
relationship status, etc
** You will waste less time and get better answers **

hope794

  • Major Contributor
  • ****
  • Country: it
  • Offline Offline
  • Gender: Male
  • Posts: 350
Re: Covid 19 may be helpful
« Reply #1 on: June 19, 2020, 09:39:51 AM »

I hope so, bro.
Logged
24 yo from Italy.Peyronie's probably since 2014.Since then,penis bends of about 10-15°, with a slight twist to the left.Moderate Erectile Dysfunction since 2 years and things getting worse.From pornstar-like to moderately depressed,but still fighting for a solution.

Patientxyz1992

  • This member has been warned for abusive behavior/inappropriate language.!
  • Voting Member
  • **
  • Country: hr
  • Offline Offline
  • Gender: Male
  • Posts: 47
Re: Covid 19 may be helpful
« Reply #2 on: June 20, 2020, 09:22:09 AM »

Hate to be pessimistic but equally possible to stuck with dick fibrosis + lung fibrosis till the rest of life...
Logged

skunkworks

  • Global Moderator
  • ****
  • Country: au
  • Offline Offline
  • Gender: Male
  • Posts: 1601
Re: Covid 19 may be helpful
« Reply #3 on: June 20, 2020, 10:37:57 AM »

More time for traction if you're working from home!
Logged
This is an emotionally destructive condition, we all have it, let's be nice to each other.

Review of current treatment options by Levine and Sherer]

Hontas

  • Major Contributor
  • ****
  • Country: 00
  • Offline Offline
  • Gender: Male
  • Posts: 378
Re: Covid 19 may be helpful
« Reply #4 on: July 03, 2020, 07:10:29 AM »

I am pretty sure it will be made impossible for you to buy a certain drug even if it works perfectly on lungs. With the current agenda of world politics where limp dick leaders want to cut every other men's penis off, i doubt we will ever have an actual solution.

To add to this, i don't think they are connected at all. I probably already had a COVID infection which was the most laughable illness i had. I legit only coughed for two days and then recovered. This disease is only lethal in high doses. Which means it is nothing like Peyronie's or connective tissue fibrosis in particular. This is rather an immune system shutdown/cytokine storm related due to HIGH viral load, not due to the virus itself.

Sorry for all the negativity, but i hate to see people full of unrealistic expectations, i also do hope to live a good and fulfilling life as much as you guys but we have to be smarter about it. All the power to the people working this site inside out. I haven't been able to be here due to personal reasons but am on a close lookout for progress.

This can't even possibly be solved by one billionaire so it's good to have woke people and masses that will actually pressure medical community into finding actual solutions for this connective tissue disease. They won't just fix our dicks from kindness of their hearts. I am sorry but this is the reality.
Logged

CrookedJohnson

  • Voting Member
  • **
  • Country: us
  • Offline Offline
  • Gender: Male
  • Posts: 6
Re: Covid 19 may be helpful
« Reply #5 on: July 05, 2020, 01:21:26 PM »


June 08, 2020 07:00 ET | Source: FibroGen, Inc
SAN FRANCISCO, June 08, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the initiation of an open-label, randomized, parallel-arm study investigating the efficacy and safety of pamrevlumab versus standard of care in patients with severe coronavirus 2019 (COVID-19) infection. The trial is being conducted by Professor Luca Richeldi, M.D., Ph.D., Head of the Division of Pulmonary Medicine at Fondazione Policlinico Universitario A. Gemelli IRCCS, and Professor of Respiratory Medicine at Catholic University of the Sacred Heart in Rome, Italy.

BOREA is a Phase 2/3 investigator-initiated clinical trial investigating the efficacy and safety of pamrevlumab in approximately 68 patients hospitalized with COVID-19. The primary objective of this study is to assess the effect of pamrevlumab on blood oxygenation in patients with COVID-19 infection. Patients will be randomized to treatment with pamrevlumab or standard of care in a 1:1 ratio. Based on the investigator’s decision, a subgroup of patients may continue treatment for up to 12 weeks.

“Recent data indicate the presence of interstitial pneumonia in the majority of hospitalized patients infected with COVID-19. The interstitial pneumonia is usually bilateral and leads to decreased blood oxygen levels, respiratory failure, intubation, and, ultimately, death in a significant proportion of patients who require mechanical ventilation,” said Elias Kouchakji, M.D., Senior Vice President, Clinical Development, Drug Safety, and Pharmacovigilance, FibroGen. “Connective tissue growth factor (CTGF) may promote vascular leakage and lead to pulmonary edema. Administration of pamrevlumab, an anti-CTGF monoclonal antibody, may reverse this edema, and thus improve oxygenation in patients with COVID-19-induced pneumonia.”

Pamrevlumab is a first-in-class antibody developed by FibroGen to inhibit the activity of CTGF, a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. This trial will assess pamrevlumab’s effect on patient time to and on ventilatory support, currently the most urgent need, and its potential to reduce mortality and fibrotic sequelae in the lung.
Logged
Pages: [1]   Go Up
 

Related Topics

  Subject / Started by Replies Last post
1 Replies
444 Views
Last post March 28, 2020, 10:17:00 PM
by TonySa
1 Replies
245 Views
Last post March 28, 2020, 08:38:50 PM
by peter123
0 Replies
172 Views
Last post April 08, 2020, 04:41:31 AM
by Fix This